These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36906614)

  • 1. Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD.
    Lerche S; Zimmermann M; Roeben B; Wurster I; Fries FL; Deuschle C; Waniek K; Lachmann I; Jakobi M; Joos TO; Knorpp T; Schneiderhan-Marra N; Brockmann K
    NPJ Parkinsons Dis; 2023 Mar; 9(1):38. PubMed ID: 36906614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers.
    Lerche S; Zimmermann M; Wurster I; Roeben B; Fries FL; Deuschle C; Waniek K; Lachmann I; Gasser T; Jakobi M; Joos TO; Schneiderhan-Marra N; Brockmann K
    Front Neurol; 2022; 13():834580. PubMed ID: 35280273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.
    Lerche S; Schulte C; Srulijes K; Pilotto A; Rattay TW; Hauser AK; Stransky E; Deuschle C; Csoti I; Lachmann I; Zetterberg H; Liepelt-Scarfone I; Gasser T; Maetzler W; Berg D; Brockmann K
    Mov Disord; 2017 Dec; 32(12):1780-1783. PubMed ID: 29094781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal trajectory of biofluid markers in Parkinson's disease.
    Baek MS; Lee MJ; Kim HK; Lyoo CH
    Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies.
    Bellomo G; Paolini Paoletti F; Chipi E; Petricciuolo M; Simoni S; Tambasco N; Parnetti L
    Diagnostics (Basel); 2020 Nov; 10(12):. PubMed ID: 33256252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.
    Lerche S; Machetanz G; Wurster I; Roeben B; Zimmermann M; Pilotto A; Preische O; Stransky E; Deuschle C; Hauser AK; Schulte C; Lachmann I; Waniek K; Gasser T; Berg D; Maetzler W; Brockmann K
    Mov Disord; 2019 Jul; 34(7):1069-1073. PubMed ID: 31189032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease: evolution of cognitive impairment and CSF Aβ
    Lerche S; Wurster I; Röben B; Machetanz G; Zimmermann M; Bernhard F; Stransky E; Deuschle C; Schulte C; Hansson O; Zetterberg H; Gasser T; Berg D; Maetzler W; Brockmann K
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):165-170. PubMed ID: 30254084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding.
    Wurster I; Quadalti C; Rossi M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; la Fougere C; Doppler K; Gasser T; Bender B; Parchi P; Brockmann K
    NPJ Parkinsons Dis; 2022 Sep; 8(1):117. PubMed ID: 36109514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.